Absci (ABSI) Share-based Compensation (2020 - 2026)
Absci (ABSI) posted Share-based Compensation of $4.4 million for Q1 2026, up 2.89% sequentially from $4.3 million in Q4 2025, and down 10.85% YoY from $4.9 million in Q1 2025.
Absci (ABSI) Share-based Compensation (2020 - 2026) Analysis & Trends
Absci has reported Share-based Compensation for 7 years, with the latest figure at $4.4 million in Q1 2026.
- Quarterly Share-based Compensation fell 10.85% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.8 million (down 14.38% YoY) and the FY2025 annual result came in at $18.3 million, down 5.81% from the prior year.
- Share-based Compensation rose to $4.4 million in Q1 2026 per ABSI's latest filing, from $4.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $19.0 million in Q4 2024 and troughed at -$11.4 million in Q4 2022.
- A 5-year average of $3.4 million and a median of $4.2 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 1500.38% in 2022, down 452.88% in 2022.
- Over 5 years, Share-based Compensation stood at -$11.4 million in 2022, then surged by 200.1% to $11.4 million in 2023, then soared by 66.6% to $19.0 million in 2024, then plunged by 77.62% to $4.3 million in 2025, then rose by 2.89% to $4.4 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $4.4 million, $4.3 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 5.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.24 Mn |
| Jun 30, 2026 | 5.24 Mn |
| Mar 31, 2026 | 4.38 Mn |
| Mar 31, 2026 | 4.38 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Dec 31, 2025 | 4.26 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.75 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 19.02 Mn |
| Dec 31, 2024 | 19.02 Mn |
| Sep 30, 2024 | -8.45 Mn |
| Sep 30, 2024 | -8.45 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Jun 30, 2024 | 5.29 Mn |
| Mar 31, 2024 | 3.59 Mn |
| Mar 31, 2024 | 3.59 Mn |